Table of Contents Author Guidelines Submit a Manuscript
International Journal of Endocrinology
Volume 2016 (2016), Article ID 7964523, 14 pages
http://dx.doi.org/10.1155/2016/7964523
Research Article

Prognostic Value of Invasion, Markers of Proliferation, and Classification of Giant Pituitary Tumors, in a Georeferred Cohort in Brazil of 50 Patients, with a Long-Term Postoperative Follow-Up

1Department of Endocrinology, Faculty of Medicine, University of Brasilia, Brasilia, Brazil
2Institute of Geosciences, University of Brasilia, Brasilia, Brazil
3Department of Neurosurgery, Faculty of Medicine, University of Brasilia, Brasilia, Brazil
4Department of Pathology, Faculty of Medicine, University of Brasilia, Brasilia, Brazil

Received 27 November 2015; Revised 9 March 2016; Accepted 30 June 2016

Academic Editor: Andrea G. Lania

Copyright © 2016 Juliano Coelho de Oliveira Zakir et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. K. Kovacs and E. Horvath, “Pathology of pituitary tumors,” Endocrinology and Metabolism Clinics of North America, vol. 16, no. 3, pp. 529–551, 1987. View at Google Scholar · View at Scopus
  2. “Central brain tumor registry of the United States 2007-2008,” Central Brain Tumor Registry of the United States Statistical Report, 2008.
  3. G. Jefferson, “Extrasellar extensions of pituitary adenomas,” Proceedings of the Royal Society of Medicine, vol. 33, pp. 433–458, 1940. View at Google Scholar
  4. G. Jefferson, The Invasive Adenomas of the Anterior Pituitary, Charles C. Thomas, Springfield, Ill, USA, 2nd edition, 1972.
  5. M. Buchfelder, “Management of aggressive pituitary adenomas: current treatment strategies,” Pituitary, vol. 12, no. 3, pp. 256–260, 2009. View at Publisher · View at Google Scholar · View at Scopus
  6. A. I. Mccormack, J. A. H. Wass, and A. B. Grossman, “Aggressive pituitary tumours: the role of temozolomide and the assessment of MGMT status,” European Journal of Clinical Investigation, vol. 41, no. 10, pp. 1133–1148, 2011. View at Publisher · View at Google Scholar · View at Scopus
  7. G. Raverot, F. Castinetti, E. Jouanneau et al., “Pituitary carcinomas and aggressive pituitary tumours: merits and pitfalls of temozolomide treatment,” Clinical Endocrinology, vol. 76, no. 6, pp. 769–775, 2012. View at Publisher · View at Google Scholar · View at Scopus
  8. R. V. Lloyd, K. Kovacs, W. F. Young Jr. et al., “Pituitary tumours: introduction,” in Tumours of the Pituitary, Chapter 1. Pathology and Genetics of Tumours of Endocrine Organs, R. A. DeLellis, R. V. Lloyd, P. U. Heitz, and C. Eng, Eds., pp. 10–13, World Hearth Organization Classification of Tumours. IARC Press, Lyon, Paris, 2004. View at Google Scholar
  9. I. Zemmoura, A. Wierinckx, A. Vasiljevic, M. Jan, J. Trouillas, and P. François, “Aggressive and malignant prolactin pituitary tumors: pathological diagnosis and patient management,” Pituitary, vol. 16, no. 4, pp. 515–522, 2013. View at Publisher · View at Google Scholar · View at Scopus
  10. J. Trouillas, P. Roy, N. Sturm et al., “A new prognostic clinicopathological classification of pituitary adenomas: a multicentric case-control study of 410 patients with 8 years post-operative follow-up,” Acta Neuropathologica, vol. 126, no. 1, pp. 123–135, 2013. View at Publisher · View at Google Scholar
  11. J.-P. Cottier, C. Destrieux, L. Brunereau et al., “Cavernous sinus invasion by pituitary adenoma: MR imaging,” Radiology, vol. 215, no. 2, pp. 463–469, 2000. View at Publisher · View at Google Scholar · View at Scopus
  12. E. Knosp, E. Steiner, K. Kitz, and C. Matula, “Pituitary adenomas with invasion of the cavernous sinus space: a magnetic resonance imaging classification compared with surgical findings,” Neurosurgery, vol. 33, no. 4, pp. 610–618, 1993. View at Publisher · View at Google Scholar · View at Scopus
  13. A. L. Edal, K. Skjödt, and H. J. Nepper-Rasmussen, “SIPAP—a new MR classification for pituitary adenomas. Suprasellar, infrasellar, parasellar, anterior and posterior,” Acta Radiologica, vol. 38, no. 1, pp. 30–36, 1997. View at Publisher · View at Google Scholar · View at Scopus
  14. J. E. A. Ferreira, P. A. de Mello, A. V. de Magalhães et al., “Caracterização clínica e imunoistoquímica dos adenomas clinicamente nao-funcionantes de hipófise,” Arquivos de Neuro-Psiquiatria, vol. 63, no. 4, pp. 1070–1078, 2005. View at Publisher · View at Google Scholar
  15. C. H. A. Botelho, A. V. De Magalhães, P. A. De Mello, F. C. Schmitt, and L. A. Casulari, “Expression of p53, KI-67 and c-erb B2 in growth hormone- and/or prolactin-secreting pituitary adenomas,” Arquivos de Neuro-Psiquiatria, vol. 64, no. 1, pp. 60–66, 2006. View at Publisher · View at Google Scholar · View at Scopus
  16. L. A. Naves, L. B. Porto, J. W. C. Rosa, L. A. Casulari, and J. W. C. Rosa, “Geographical information system (GIS) as a new tool to evaluate epidemiology based on spatial analysis and clinical outcomes in acromegaly,” Pituitary, vol. 18, no. 1, pp. 8–15, 2015. View at Publisher · View at Google Scholar · View at Scopus
  17. IOM—Institute of Medicine, “Beyond the HIPAA privacy rule: enhancing privacy, improving health through research,” HIPAA Regulations §164.514, The National Academics Press, US Department of Human Health Services, Washington, DC, USA, 2009. View at Google Scholar
  18. M. P. Armstrong, G. Rushton, and D. L. Zimmerman, “Geographically masking health data to preserve confidentiality,” Statistics in Medicine, vol. 18, no. 5, pp. 497–525, 1999. View at Google Scholar · View at Scopus
  19. G. F. Jenks, “The data model concept in statistical mapping,” International Yearbook of Cartography, vol. 7, pp. 186–190, 1967. View at Google Scholar
  20. R. McMaster, “In memoriam: George F. Jenks (1916–1996),” Cartography and Geographic Information Science, vol. 24, no. 1, pp. 56–59, 1997. View at Publisher · View at Google Scholar
  21. A. Agresti, An Introduction to Categorical Data Analysis, chapter 4, John Wiley & Sons, New York, NY, USA, 2nd edition, 2007. View at Publisher · View at Google Scholar · View at MathSciNet
  22. W. Saeger, J. Honegger, M. Theodoropoulou et al., “Clinical impact of the current WHO classification of pituitary adenomas,” Endocrine Pathology, vol. 27, no. 2, pp. 104–114, 2016. View at Publisher · View at Google Scholar
  23. W. Saeger, D. K. Lüdecke, M. Buchfelder, R. Fahlbusch, H.-J. Quabbe, and S. Petersenn, “Pathohistological classification of pituitary tumors: 10 years of experience with the German Pituitary Tumor Registry,” European Journal of Endocrinology, vol. 156, no. 2, pp. 203–216, 2007. View at Publisher · View at Google Scholar · View at Scopus
  24. G. Zada, W. W. Woodmansee, S. Ramkissoon, J. Amadio, V. Nose, and E. R. Laws Jr., “Atypical pituitary adenomas: incidence, clinical characteristics, and implications,” Journal of Neurosurgery, vol. 114, no. 2, pp. 336–344, 2011. View at Publisher · View at Google Scholar · View at Scopus
  25. A. Di Ieva, F. Rotondo, L. V. Syro, M. D. Cusimano, and K. Kovacs, “Aggressive pituitary adenomas-diagnosis and emerging treatments,” Nature Reviews Endocrinology, vol. 10, no. 7, pp. 423–435, 2014. View at Publisher · View at Google Scholar · View at Scopus
  26. G. Raverot, A. Vasiljevic, E. Jouanneau, and J. Trouillas, “A prognostic clinicopathologic classification of pituitary endocrine tumors,” Endocrinology and Metabolism Clinics of North America, vol. 44, no. 1, pp. 11–18, 2015. View at Publisher · View at Google Scholar · View at Scopus
  27. K. Thapar, B. W. Scheithauer, K. Kovacs, P. J. Pernicone, and E. R. Laws Jr., “p53 expression in pituitary adenomas and carcinomas: correlation with invasiveness and tumor growth fractions,” Neurosurgery, vol. 38, no. 4, pp. 765–771, 1996. View at Publisher · View at Google Scholar · View at Scopus
  28. S. J. Hentschel, I. E. McCutcheon, W. Moore, and F. A. Durity, “p53 and MIB-1 immunohistochemistry as predictors of the clinical behavior of nonfunctioning pituitary adenomas,” Canadian Journal of Neurological Sciences, vol. 30, no. 3, pp. 215–219, 2003. View at Publisher · View at Google Scholar · View at Scopus
  29. B. W. Scheithauer, T. A. Gaffey, R. V. Lloyd et al., “Pathobiology of pituitary adenomas and carcinomas,” Neurosurgery, vol. 59, no. 2, pp. 341–353, 2006. View at Publisher · View at Google Scholar · View at Scopus
  30. M. Suliman, J. Royds, D. Cullen et al., “Mdm2 and the p53 pathway in human pituitary adenomas,” Clinical Endocrinology, vol. 54, no. 3, pp. 317–325, 2001. View at Publisher · View at Google Scholar · View at Scopus
  31. R. Gejman, B. Swearingen, and E. T. Hedley-Whyte, “Role of Ki-67 proliferation index and p53 expression in predicting progression of pituitary adenomas,” Human Pathology, vol. 39, no. 5, pp. 758–766, 2008. View at Publisher · View at Google Scholar · View at Scopus
  32. A. Wierinckx, C. Auger, P. Devauchelle et al., “A diagnostic marker set for invasion, proliferation, and aggressiveness of prolactin pituitary tumors,” Endocrine-Related Cancer, vol. 14, no. 3, pp. 887–900, 2007. View at Publisher · View at Google Scholar · View at Scopus
  33. G. Kontogeorgos, “Predictive markers of pituitary adenoma behavior,” Neuroendocrinology, vol. 83, no. 3-4, pp. 179–188, 2006. View at Publisher · View at Google Scholar · View at Scopus
  34. F. T. Bosman, F. Carneiro, R. H. Hruban, and N. D. Theise, Eds., WHO Classification of Tumours of the Digestive System, IARC, Lyon, France, 2010.
  35. F. Salehi, A. Agur, B. W. Scheithauer, K. Kovacs, R. V. Lloyd, and M. Cusimano, “Ki-67 in pituitary neoplasms: a review—part I,” Neurosurgery, vol. 65, no. 3, pp. 429–437, 2009. View at Publisher · View at Google Scholar · View at Scopus
  36. P. H. P. de Aguiar, R. Aires, E. R. Laws et al., “Labeling index in pituitary adenomas evaluated by means of MIB-1: is there a prognostic role? A critical review,” Neurological Research, vol. 32, no. 10, pp. 1060–1071, 2010. View at Publisher · View at Google Scholar · View at Scopus
  37. R. Lath, G. Chacko, and M. J. Chandy, “Determination of Ki-67 labeling index in pituitary adenomas using MIB-1 monoclonal antibody,” Neurology India, vol. 49, no. 2, pp. 144–147, 2001. View at Google Scholar · View at Scopus
  38. K.-I. Paek, S.-H. Kim, S.-H. Song et al., “Clinical significance of Ki-67 labeling index in pituitary macroadenoma,” Journal of Korean Medical Science, vol. 20, no. 3, pp. 489–494, 2005. View at Publisher · View at Google Scholar · View at Scopus
  39. A. F. Daly and A. Beckers, “Familial isolated pituitary adenomas (FIPA) and mutations in the aryl hydrocarbon receptor interacting protein (AIP) gene,” Endocrinology and Metabolism Clinics of North America, vol. 44, no. 1, pp. 19–25, 2016. View at Publisher · View at Google Scholar · View at Scopus
  40. L. A. Naves, A. F. Daly, L. A. Dias et al., “Aggressive tumor growth and clinical evolution in a patient with X-linked acro-gigantism syndrome,” Endocrine, vol. 51, no. 2, pp. 236–244, 2016. View at Publisher · View at Google Scholar · View at Scopus
  41. L. A. Naves, M.-L. Jaffrain-Rea, S. A. C. Vêncio et al., “Aggressive prolactinoma in a child related to germline mutation in the ARYL hydrocarbon receptor interacting protein (AIP) gene,” Arquivos Brasileiros de Endocrinologia e Metabologia, vol. 54, no. 8, pp. 761–767, 2010. View at Publisher · View at Google Scholar · View at Scopus
  42. O. Cooper, G. Vlotides, H. Fukuoka, M. I. Greene, and S. Melmed, “Expression and function of ErbB receptors and ligands in the pituitary,” Endocrine-Related Cancer, vol. 18, no. 6, pp. R197–R211, 2011. View at Publisher · View at Google Scholar · View at Scopus
  43. M. M. Moasser, “The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis,” Oncogene, vol. 26, no. 45, pp. 6469–6487, 2007. View at Publisher · View at Google Scholar · View at Scopus
  44. I. Rubin and Y. Yarden, “The basic biology of HER2,” Annals of Oncology, vol. 12, supplement 1, pp. S3–S8, 2001. View at Google Scholar · View at Scopus
  45. A. Righi, P. Agati, A. Sisto et al., “A classification tree approach for pituitary adenomas,” Human Pathology, vol. 43, no. 10, pp. 1627–1637, 2012. View at Publisher · View at Google Scholar · View at Scopus
  46. J. Hardy, “Transphenoidal microsurgery of the normal and pathological pituitary,” Clinical Neurosurgery, vol. 16, pp. 185–217, 1969. View at Google Scholar · View at Scopus
  47. C. B. Wilson, “Neurosurgical management of large and invasive pituitary tumors,” in Clinical Management of Pituitary Disorders, G. T. Tindall and W. F. Collins, Eds., pp. 335–342, Raven Press, New York, NY, USA, 1979. View at Google Scholar
  48. G. Raverot, E. Jouanneau, and J. Trouillas, “Management of endocrine disease: clinicopathological classification and molecular markers of pituitary tumours for personalized therapeutic strategies,” European Journal of Endocrinology, vol. 170, no. 4, pp. R121–R132, 2014. View at Publisher · View at Google Scholar · View at Scopus